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Pengenalan: Dalam rawatan alergik rhinitis (AR), ubat montelukast mempunyai potensi 
untuk digunakan sebagai alternatif  atau sebagai tambahan kepada ubat oral antihistamine 
(OAH) atau ubat intranasal corticosteroid. 
Objektif: Untuk menilai keberkesanan ubat montelukast dalam rawatan alergik rhinitis.  
Kaedah: Kajian literatur elektronik dibuat dalam ‘Cochrane Central Register of Controlled 
Trials CENTRAL’ ‘EMBASE’ dan ‘MEDLINE’ dari 1966 sehingga 21hb Januari 2019. 
Penyelidikan yang mematuhi syarat-syarat untuk layak dinilai, iaitu ‘Randomized control 
trials(RCTs)’ yang membandingkan Montelukast dengan ‘placebo’ ataupun rawatan 
standard. Penyelidikan utama yang dinilai ialah skor gejala hidung waktu siang (DNS) dan 
skor gejala hidung waktu malam (NNS). Penyelidikan lain-lain yang dinilai skor gejala 
komposit (CSS), skor gejala mata waktu siang (DES) dan kualiti hidup (RQLQ). Meta-
analisa dilakukan menggunakan perisian Review Manager 5.3 (RevMan 2014) dan data 
dikumpulkan menggunakan model kesan rawak. 
Keputusan: Lima belas penyelidikan melibatkan 10387 peserta mematuhi syarat-syarat 
layak dinilai. Montelukast lebih berkesan apabila dibandingkan dengan ‘placebo’ dalam 
membantu DNS (MD -0.12, 95% CI -0.15 to -0.08; P < 0.001), NNS (MD -0.09, 95% CI -
0.13 to -0.05; P < 0.001), CSS (MD -0.08, 95% CI -0.11 to -0.06; P < 0.001), DES (MD -
0.17, 95% CI -0.33 to -0.02; P < 0.030) and RQLQ (MD -0.34, 95% CI -0.49 to -0.20; P < 
0.001). OAH lebih berkesan apabila dibandingkan dengan  montelukast dalam membantu 
DNS (MD 0.08, 95% CI 0.03 to 0.13; P=0.002), CSS (MD 0.03, 95% CI -0.02 to 0.07; 
P=0.270), DES (MD 0.06, 95% CI 0 to 0.12; P=0.040) and RQLQ (MD 0.03, 95% CI -0.05 
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to 0.12; P=0.430). Montelukast lebih berkesan dari OAH dalam membantu NNS (MD -0.03, 
95% CI -0.08 to 0.03; P=0.330). Semburan Intranasal fluticasone lebih berkesan berbanding 
montelukast dalam membantu DNS (MD 0.71, 95% CI 0.44 to 0.99; P < 0.001) dan NNS 
(MD 0.63, 95% CI 0.29 to 0.97; P < 0.001). Kombinasi montelukast dan OAH lebih berkesan 
berbanding OAH dalam membantu DNS (MD -0.15, 95% CI -0.27 to -0.03; P =0.010), NNS 
(MD -0.16, 95% CI -0.28 to -0.05; P =0.006), CSS (MD -0.12, 95% CI -0.25 to -0.01; P 
=0.070), DES (MD -0.12, 95% CI -0.30 to 0.06; P =0.180) and RQLQ (MD -0.10, 95% CI -
0.28 to 0.08; P =0.290). Kombinasi montelukast dan OAH lebih berkesan berbanding 
montelukast dalam membantu DNS (MD 0.15, 95% CI 0.08 to 0.21; P<0.001), NNS (MD 
0.05, 95% CI -0.09 to 0.19; P=0.510), CSS (MD 0.1, 95% CI 0.03 to 0.17; P=0.007), DES 
(MD 0.18, 95% CI 0 to 0.36; P=0.050) dan RQLQ (MD 0.07 95% CI -0.15 to 0.29; P=0.530). 
Kesimpulan: Montelukast berkesan dalam rawatan pesakit AR yang mempunyai gejala 
hidung waktu malam dan juga sebagai terapi kombinasi bersama-sama OAH dalam 













Introduction: In treating allergic rhinitis (AR), montelukast has the potential to be used as 
an alternative or addition to oral antihistamine (OAH) or intranasal corticosteroid. 
Objectives: To assess the effectiveness of montelukast in treating AR. 
Methods: An electronic literature search was performed using Cochrane Central Register of 
Controlled Trials, EMBASE and MEDLINE from 1966 to 21st January 2019. The eligibility 
criteria were randomized control trials comparing montelukast with placebo or other standard 
treatments. The primary outcomes assessed were daytime nasal symptom score (DNS) and 
nighttime nasal symptom score (NNS). The secondary outcomes assessed were composite 
nasal symptom score (CSS), daytime eyes symptom score (DES) and rhinoconjunctivitis 
quality of life questionnaires (RQLQ). Meta-analysis was done using Review Manager 5.3 
software based on the random-effects model. 
Results: Fifteen studies of 10387 participants met the inclusion criteria.  Montelukast was 
effective than placebo in improving DNS (MD -0.12, 95% CI -0.15 to -0.08; P < 0.001), NNS 
(MD -0.09, 95% CI -0.13 to -0.05; P < 0.001), CSS (MD -0.08, 95% CI -0.11 to -0.06; P < 
0.001), DES (MD -0.17, 95% CI -0.33 to -0.02; P < 0.030) and RQLQ (MD -0.34, 95% CI -
0.49 to -0.20; P < 0.001). OAH was superior than montelukast in improving DNS (MD 0.08, 
95% CI 0.03 to 0.13; P=0.002), CSS (MD 0.03, 95% CI -0.02 to 0.07; P=0.270), DES (MD 
0.06, 95% CI 0 to 0.12; P=0.040) and RQLQ (MD 0.03, 95% CI -0.05 to 0.12; P=0.430). 
Montelukast was superior than OAH in improving NNS (MD -0.03, 95% CI -0.08 to 0.03; 
P=0.330). Intranasal fluticasone spray was superior than montelukast in improving DNS 
(MD 0.71, 95% CI 0.44 to 0.99; P < 0.001) and NNS (MD 0.63, 95% CI 0.29 to 0.97; P < 
0.001). A combined montelukast and OAH was superior than OAH in in improving DNS 
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(MD -0.15, 95% CI -0.27 to -0.03; P =0.010), NNS (MD -0.16, 95% CI -0.28 to -0.05; P 
=0.006), CSS (MD -0.12, 95% CI -0.25 to -0.01; P =0.070), DES (MD -0.12, 95% CI -0.30 
to 0.06; P =0.180) and RQLQ (MD -0.10, 95% CI -0.28 to 0.08; P =0.290). A combined 
montelukast and OAH was superior than montelukast improving DNS (MD 0.15, 95% CI 
0.08 to 0.21; P<0.001), NNS (MD 0.05, 95% CI -0.09 to 0.19; P=0.510), CSS (MD 0.1, 95% 
CI 0.03 to 0.17; P=0.007), DES (MD 0.18, 95% CI 0 to 0.36; P=0.050) and RQLQ (MD 0.07 
95% CI -0.15 to 0.29; P=0.530). 
Conclusion: Montelukast is effective in treating AR patients with nocturnal symptoms and 





Description of the condition 
Allergic rhinitis is a disease which imposes a universal burden [1]. It may occur 
simultaneously with other diseases such as asthma. In fact, the concept of ‘one airway one 
disease’ shows that both these pathologies frequently develop hand in hand [2, 3].  
Worldwide, the prevalence of allergic rhinitis varies. The prevalence reported in Western 
Europe was 23%, and in the Asian population, they were as high as 40-46% [3]. Allergic 
rhinitis can be regarded as the most prevalent immune-mediated disease with an increasing 
presence [4]. The allergic reaction that occurs in the disease is now regarded as a dynamic 
process rather than a one-off event. Allergic rhinitis occurs after a sensitized individual is 
exposed to a specific trigger, for example, house dust mite, pollen or dander [5]. A cascade 
of events following the trigger occur at a molecular level that leads to classical symptoms of 
allergic rhinitis. 
 
The classical symptoms, which occur in allergic rhinitis, are sneezing, rhinorrhea, nasal 
obstruction, and pruritis [6]. Hyposmia is also another symptom of allergic rhinitis. As much 
as 60% of allergic rhinitis patients have been shown to suffer from anomalies of smell [7]. 
Apart from these, excessive daytime somnolence and sleep disturbances are known 
symptoms, which occur due to nocturnal nasal blockage [8]. In extreme cases, there would 
be increased pressure within the paranasal sinuses. In other instances, patients may develop 
ear fullness or earache as a result of eustachian tube dysfunction [9]. Of all the symptoms 





Based on the symptoms, allergic rhinitis can be divided into persistent or intermittent 
(temporal) and mild / moderate-severe (severity) using the ‘Allergic Rhinitis and its Impact 
on Asthma Guide’ [11] .There is another new classification by Okubo et al. that is the 
sneezing type or the obstruction type [12]. Based on Japanese guidelines, sneezing and 
rhinorrhea is caused by histamine and classified as one ‘subtype’ of allergic rhinitis. 
Obstruction subtype is due to leukotriene mediated symptoms of nasal blockage. Even 
though allergic rhinitis is never life-threatening, it’s significance is always underplayed [1]. 
Allergic rhinitis not only affects the quality of life of the patient, but it also has a negative 
implication on society [6, 13]. School absenteeism and economic loss due to financing of 
medication are among its downside [5]. 
 
Description of the intervention 
The basis of allergic rhinitis is a type I hypersensitivity response of the nasal mucosa due to 
a trigger (allergen), mediated by Immunoglobulin E [9, 1]. During this response, there is 
plenty of chemoattraction of cells and molecules [4]. A salient characteristic of allergic 
rhinitis is the aggregation of eosinophils [14]. Besides the presence of inflammatory cells 
(mast cells, eosinophils, neutrophils, and T cells), there is an increase in proinflammatory 
mediators like histamine and leukotrienes in the nasal secretions [15]. Although histamine 
was first described in 1910, leukotriene was relatively new and was only described in 1979 
[16, 17]. It is now understood that leukotrienes like LTC4, LTD4 and LTE4 (all 3 are known 
as cysteinyl leukotrienes, CysLTs) are eosinophilic chemoattractants, (the key in allergic 
rhinitis). As such, montelukast blocks these leukotriene receptors and prevents its action. The 
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actions of CysLTs namely are :i) increase vascular permeability ii) mucous production iii)  
smooth muscles constriction iv) migration of eosinophils [1]. 
 
It has also been understood that histamine is crucial in the development of symptoms like 
sneezing and itching (due to nervous stimulation) as well as rhinorrhea (due to glandular 
secretions). As such, antihistamine medication is well for the above symptoms, but not 
effective against obstruction; in contrast to leukotriene, which primarily causes nasal block 
and increases nasal airway resistance [1, 15] .  
 
How the intervention might work 
Allergen avoidance and environmental control are crucial in the treatment of allergic rhinitis 
[18]. Nonetheless, montelukast is an effective drug for treatment. The principal treatment in 
allergic rhinitis is intranasal steroid [19, 20]. However, both antihistamine and 
antileukotriene have shown to be as effective in the treatment of allergic rhinitis [15]. The 
effect of histamine on the nasal block is short-lived and only noticeable at high concentrations. 
Leukotriene, however, mainly functions to increases nasal block. Antileukotriene treatment 
was found to be comparable to antihistamines and intranasal corticosteroid. Leukotriene 
levels are increased in allergic rhinitis patients following allergen exposure, which justifies 
the role of montelukast in allergic rhinitis treatment [18]. There has been a significant 
improvement in the quality of life after montelukast treatment when combined with intranasal 






Why it is important to do this review 
Nasal congestion is one of many important symptoms of allergic rhinitis. Effectiveness of 
montelukast in curing symptoms is important to be assessed. Reviews on Montelukast have 
been performed in 2009 [21] and 2004 [22]. New trials regarding Montelukast for the 
treatment of allergic rhinitis have emerged. The current review serves as an update to whether 
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The objective of this systematic review and meta-analysis was to determine the effectiveness 
of montelukast in allergic rhinitis 
Primary outcomes 
1. Daytime nasal symptom score 
2. Nighttime nasal symptom score 
Secondary outcomes 
1. Composite symptom score 
2. Daytime eye score 
3. Rhino conjunctivitis quality of life  
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Introduction In treating allergic rhinitis (AR), montelukast has the potential to be used as an 
alternative or addition to oral antihistamine (OAH) or intranasal corticosteroid. 
Objective To assess the effectiveness of montelukast in treating AR. 
Methods An electronic literature search was performed using Cochrane Central Register of 
Controlled Trials, EMBASE and MEDLINE from 1966 to 21st January 2019. The eligibility 
criteria were randomized control trials comparing montelukast with placebo or other standard 
treatments. The primary outcomes assessed were daytime nasal symptom score (DNS) and 
nighttime nasal symptom score (NNS). The secondary outcomes assessed were composite 
nasal symptom score (CSS), daytime eyes symptom score (DES) and rhinoconjunctivitis 
quality of life questionnaires (RQLQ). Meta-analysis was done using Review Manager 5.3 
software based on the random-effects model. 
Results Fifteen studies of 10387 participants met the inclusion criteria.  Montelukast was 
effective than placebo in improving DNS (MD -0.12, 95% CI -0.15 to -0.08; P < 0.001), NNS 
(MD -0.09, 95% CI -0.13 to -0.05; P < 0.001), CSS (MD -0.08, 95% CI -0.11 to -0.06; P < 
0.001), DES (MD -0.17, 95% CI -0.33 to -0.02; P < 0.030) and RQLQ (MD -0.34, 95% CI -
0.49 to -0.20; P < 0.001). OAH was superior than montelukast in improving DNS (MD 0.08, 
95% CI 0.03 to 0.13; P=0.002), CSS (MD 0.03, 95% CI -0.02 to 0.07; P=0.270), DES (MD 
0.06, 95% CI 0 to 0.12; P=0.040) and RQLQ (MD 0.03, 95% CI -0.05 to 0.12; P=0.430). 
Montelukast was superior than OAH in improving NNS (MD -0.03, 95% CI -0.08 to 0.03; 
P=0.330). Intranasal fluticasone spray was superior than montelukast in improving DNS 
(MD 0.71, 95% CI 0.44 to 0.99; P < 0.001) and NNS (MD 0.63, 95% CI 0.29 to 0.97; P < 
0.001). A combined montelukast and OAH was superior than OAH in in improving DNS 
(MD -0.15, 95% CI -0.27 to -0.03; P =0.010), NNS (MD -0.16, 95% CI -0.28 to -0.05; P 
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=0.006), CSS (MD -0.12, 95% CI -0.25 to -0.01; P =0.070), DES (MD -0.12, 95% CI -0.30 
to 0.06; P =0.180) and RQLQ (MD -0.10, 95% CI -0.28 to 0.08; P =0.290). A combined 
montelukast and OAH was superior than montelukast improving DNS (MD 0.15, 95% CI 
0.08 to 0.21; P<0.001), NNS (MD 0.05, 95% CI -0.09 to 0.19; P=0.510), CSS (MD 0.1, 95% 
CI 0.03 to 0.17; P=0.007), DES (MD 0.18, 95% CI 0 to 0.36; P=0.050) and RQLQ (MD 0.07 
95% CI -0.15 to 0.29; P=0.530). 
Conclusion Montelukast is effective in treating AR patients with nocturnal symptoms and as 




1. Montelukast is effective in treating the overall symptoms of allergic rhinitis when 
compared against placebo. 
2. Montelukast is effective in treating the nighttime symptoms of allergic rhinitis when 
compared against oral antihistamine. 
3. Combination therapy of montelukast with oral antihistamine is superior to oral 











Allergic rhinitis (AR) is regarded as the most prevalent challenging immune-mediated 
disease to treat [1]. Allergic rhinitis occurs after a sensitized individual is exposed to a 
specific trigger, such as house dust mite, pollen or dander [2]. After exposure to the triggering 
factor, a cascade of events at a molecular level follows that leads to classical symptoms of 
AR. The classical symptoms in AR are sneezing, rhinorrhea, nasal obstruction, itchiness and 
occasionally hyposmia [3, 4].  
Sneezing, itchiness and rhinorrhea are caused by histamine while obstruction is due to 
leukotriene mediated effect [5]. Nasal blockage can lead to excessive daytime somnolence 
and sleep disturbances. Excessive daytime somnolence and sleep disturbances are known 
symptoms, which occur due to nocturnal nasal block [6]. Of these, the most disturbing 
symptom and the most difficult to treat is nasal obstruction [7]. Montelukast acts by blocking 
the leukotriene receptors, thus preventing its action and may improve AR symptoms, notably 
nasal block. 
A review by Wei [8] showed montelukast is not as effective as an oral antihistamine (OAH) 
in improving the quality of life in AR patients. Another review by Xiao et al [9] found OAH 
more efficacious than montelukast in relieving AR symptoms. Both reviews, however, 
recommended further investigation into the role of montelukast in the treatment of AR [8, 9]. 
Hence, the role of montelukast in AR management remains unclear, and its potential benefit 
in the management algorithm of AR is not fully understood. To determine the role of 
montelukast in AR management, we conducted a meta-analysis assessing its efficacy in 





Our systematic review was done according to a protocol published in PROSPERO with 
identification serial number as CRD 42019133172. The methods and reporting were based 
on the Cochrane Collaboration [10] and the preferred reporting items for systematic reviews 
and meta-analyses statement [11]. The evaluation was done according to the Grading of 
Recommendations Assessment, Development, and Evaluation (GRADE)  guideline [12]. 
2.1 Eligibility criteria 
Randomized control trials (RCTs) comparing montelukast with placebo, combination 
therapy or other standard treatments, were included. Cross-over studies were excluded due 
to the carry-over effect. The eligibility criteria were all age groups diagnosed with AR (with 
allergic conjunctivitis or urticaria or asthma) of either gender or ethnicity. Allergic rhinitis 
must be diagnosed by clinicians. Studies in which diagnosis of AR was based on the 
participant or caregiver report alone were excluded. The follow-up period for outcomes was 
a minimum of 2 weeks. 
2.2 Search strategy 
An electronic literature search was performed using Cochrane Central Register of Controlled 
Trials (CENTRAL), EMBASE and MEDLINE from 1966 to January 2019. The search was 
performed using the keywords ‘allergic rhinitis’ and ‘montelukast’. We checked the 
reference list of identified RCTs and review articles to find unpublished trials or trials not 
identified by electronic searches. We searched for ongoing trials through the World Health 
Organization International Clinical Trials Registry Platform http://www.who.int/ictrp/en/ 





2.3 Study selection 
Review authors (MK, NMN) scanned the titles and abstracts from the searches and obtained 
full-text articles when they appeared to meet the eligibility criteria, or when there was 
insufficient information to assess the eligibility. Eligibility of the studies was assessed 
independently, and the reasons for exclusion were documented. Any disagreements between 
the review authors were resolved by the third author (BA). We contacted the authors if 
clarification was needed. 
2.4 Data extraction 
Data were extracted using data collection forms. The reviewers (MK, NMN) independently 
extracted the trial characteristics (single or multicenter, country), baseline characteristics of 
the patients (age, sex, disease status), inclusion and exclusion criteria, the description of the 
intervention (thresholds, duration) and outcomes. If information was unclear or missing, the 
corresponding authors of the relevant trials were contacted. The primary outcomes were 
daytime nasal symptom score (DNS) and nighttime nasal symptom score (NNS). The 
secondary outcomes were composite nasal symptom score (CSS), daytime eyes symptom 
score (DES) and rhinoconjunctivitis quality of life questionnaires (RQLQ). 
2.5 Risk of bias assessment 
Risk of bias was done on all studies based on the Cochrane Handbook [10]. The risk of bias 
for the trials was classified into low risk, unclear risk or high risk. We assessed the risk of 
bias based on random sequence generation, allocation concealment, blinding of participants 
and personnel, blinding of outcome assessors, completeness of outcome data, the selectivity 
of outcome reporting and other bias. We resolved any disagreements by discussion. 
2.6 Grading quality of evidence 
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We assessed the quality of evidence for primary and secondary outcomes according to 
GRADE methodology [12], classified as very low, low, moderate, or high, based on the risk 
of bias, inconsistency, indirectness, imprecision and publication bias. 
2.7 Statistical analysis  
We undertook meta-analyses using Review Manager 5.3 software (RevMan 2014) and used 
the random-effects model to pool data. We assessed the presence of heterogeneity in two 
steps. First, we assessed obvious heterogeneity at face value by comparing populations, 
settings, interventions and outcomes. Second, we assessed statistical heterogeneity by means 
of the I2 statistic. Heterogeneity was interpreted as follows: 0 % to 40 % might not be 
important; 30 % to 60 % may represent moderate heterogeneity; 50 % to 90 % may represent 
substantial heterogeneity, and 75 % to 100 % would be considerable heterogeneity [10].  
We measured the treatment for continuous outcomes using mean differences (MDs) or 
standard mean difference (SMD) and relative risk (RR) with 95% confidence intervals (CIs) 
depending on data availability. We conducted subgroup analyses on the duration of treatment. 












3. Results and analysis 
3.1 Study selection 
There were 578 records identified by database searching. There was one additional record 
identified using other sources. After removing the duplicates, there were 461 records. The 
records were screened, and 447 of them were excluded. Fourteen of the full-text articles 
comprising of 15 studies (1 article described 2 studies) were assessed for eligibility and 
included in the qualitative and quantitative synthesis (Figure 1). 
 
3.2 Participants  
Fifteen studies of 10387 participants met the inclusion criteria [13-26]. The characteristics of 
the included studies are shown in Table 1. Four of the studies were single-centre studies [13, 
14, 18, 24], and the remaining 11 were multicenter studies [15-17, 19-23, 25, 26].  One study 
reported the mean age for the treatment and control groups, which was 33.6 years and 34.15 
years, respectively [24]. Four studies reported the overall mean age of 30.75, ranging from 
13 to 81 years [13, 17, 18, 26]. The remaining 10 studies reported age range from 15 to 81 
years old [14-16, 19-23, 25]. All patients were required to demonstrate a positive AR history 
of at least 2 years in 11 studies [15-20, 23-26], a positive allergic reaction for 2 seasons in 2 
studies [21, 22], clinical history of AR of 1 year in 1 study [14] and clinical history of AR 
irrespective of duration in 1 study [13]. All except 1 study [14] required patients to 
demonstrate a positive skin prick test. 
3.3 Intervention 
Participants in the studies were randomized into either two, three, four or five treatment 
groups. There were 6 studies with 2 treatment groups [13, 14, 17, 22, 24, 26]. Of these, 3 
studies compared montelukast against placebo [17, 24, 26] and the remaining 3 compared i) 
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montelukast and fluticasone against placebo and fluticasone [13], ii) montelukast and 
levocetirizine against levocetirizine [14], and iii) montelukast against fluticasone [22].   
There were 3 studies with 3 arms evaluating i) montelukast ii) loratadine and iii) placebo [15, 
16, 25]. There were 4 studies with 4 arms; in which 2 studies evaluated i) montelukast, ii) 
placebo, iii) loratadine and iv) montelukast and loratadine [20, 23]; 1 study evaluated i) 
formoterol inhaler and fluticasone nasal spray, ii) formoterol inhaler and montelukast, iii) 
formoterol inhaler alone and iv) montelukast alone [21], and the remaining 1 study evaluated, 
i) fluticasone nasal spray, ii) montelukast, iii) montelukast and loratadine and iv) placebo 
[18]. There were 2 studies with 5 arms evaluating i) montelukast, ii) montelukast and 
loratadine, iii) loratadine alone and iv) a higher dose of montelukast [19] or beclomethasone 
nasal spray [20] and v) placebo.  
Montelukast was given as an oral form in all 15 studies [13-26]. It was given in the evening 
or at bedtime in 8 studies [13, 14, 16, 17, 19, 23, 25, 26] and in the morning in 2 studies [15, 
18]. In 5 studies, the time of day at which montelukast was administered was not stated [20-
22, 24]. In 14 studies, irrespective of the treatment group, the dose of montelukast prescribed 
was 10 mg either as monotherapy or combined treatment [13-18, 20-26]. Only in 1 study, 
montelukast was given at a higher dose of 20 mg in the treatment group [19]. A period of 2 
weeks of treatment was reported in 8 studies [16, 19, 20, 22, 23, 25, 26] while 7 studies 
reported treatment period of two to eight weeks [13-15, 17, 18, 21, 24]. 
3.4 Outcomes  
The primary outcomes were reported in 14 studies [13-23, 25, 26] while the secondary 
outcomes were reported in 12 studies [13-17, 19, 20, 23-26]. The tool for assessing the 
RCQOL was a questionnaire developed by Juniper and Guyatt [27], which was used in 7 
